An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe

References

• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:247–51.
   Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Dengener. 2014;15:610–17.
   PubMed Web of Science ®Google Scholar
• The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase 3 clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl.1). [Epub ahead of print]. doi. 10.1080/21678421.2017.1363780.
   Google Scholar
• Takahashi F, Takei K, Tsuda K, Palumbo J. Post-hoc analysis of study MCI186-17 (extension study of MCI186-16) for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl.1). [Epub ahead of print]. doi. 10.1080/21678421.2017.1361441.
   Web of Science ®Google Scholar
• Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomized, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;(Suppl.1). [Epub ahead of print]. doi:10.1080/21678421.2017.1361443.
   Web of Science ®Google Scholar
• Ihara Y, Nobukuni K, Takata H, Hayabara T. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res. 2005;27:105–8.
   PubMed Web of Science ®Google Scholar
• Murata T, Ohtsuka C, Terayama Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2008;267:66–9.
   PubMed Web of Science ®Google Scholar
• Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med. 2000;29:652–28.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69:2064–74.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9:177–83.
   PubMed Web of Science ®Google Scholar
• Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci. 2017;44:90–5.
   PubMed Web of Science ®Google Scholar
• Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004;62:1758–65.
   PubMed Web of Science ®Google Scholar
• Baillet A, Chanteperdrix V, Trocmé C, Casez P, Garrel C, Besson G. The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem Res. 2010;35:1530–7.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129–31.
   PubMed Web of Science ®Google Scholar
• Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr. Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42:644–54.
   PubMed Web of Science ®Google Scholar
• LoGerfo A, Chico L, Borgia L, Petrozzi L, Rocchi A, D'Amelio A, et al. Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients. Oxid. Med Cell Longev. 2014;2014:432626.
   PubMed Web of Science ®Google Scholar
• Pasquinelli A, Chico L, Pasquali L, Bisordi C, Lo Gerfo A, Fabbrini M, et al. Gly482Ser PGC-1α gene polymorphism and exercise-related oxidative stress in amyotrophic lateral sclerosis patients. Front Cell Neurosci. 2016;10:102.
   PubMed Web of Science ®Google Scholar
• Siciliano G, Piazza S, Carlesi C, Del Corona A, Franzini M, Pompella A, et al. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. J Neurol. 2007 May;254:575–80.
   PubMed Web of Science ®Google Scholar
• Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep 2016;21:104–12.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51:1501–8.
   PubMed Web of Science ®Google Scholar
• Oh SI, Baek S, Park JS, Piao L, Oh KW, Kim SH. Prognostic role of serum levels of uric acid in amyotrophic lateral sclerosis. J Clin Neurol. 2015;11:376–82.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Guo X, Wei Q, Song W, Cao B, Huang R, et al. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metab Brain Dis. 2014;29:771–5.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285:95–9.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011;258:238–43.
   PubMed Web of Science ®Google Scholar
• Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD. Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev. 2013;2013:408681.
   PubMed Web of Science ®Google Scholar
• D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65:509–27.
   PubMed Web of Science ®Google Scholar
• Japan Society of Neurology Treatment Guidelines. ALS treatment guidelines 2002. Clinical Neurology. 2002; (Japanese).
   Google Scholar
• Japan Society of Neurology. ALS clinical practice guidelines 2013. Nankodo Co., Ltd., Tokyo 2013.
   Google Scholar
• Miller RG, Sufit R, Mitsumoto H, Gelinas DF, Brooks BR. ALS standard of care consensus. Neurology. 1997;48(Suppl 4):S33–S7.
   Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. for the world federation of neurology research group on motor neuron disease. El Escorial Revised: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman O, Sufit R, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1999;52:1311–23.
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–26.
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227–33.
   PubMed Web of Science ®Google Scholar
• EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719–25.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
   PubMed Web of Science ®Google Scholar
• Doi Y, Atsuta N, Sobue G, Morita M. Nakano I. Prevalence and incidence of amyotrophic lateral sclerosis in Japan. J Epidemiol. 2014;24:494–9.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Nagaoka U, Nakayama Y, Kawata A, Kugimoto C, Kuroiwa Y, et al. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler. 2012;13:363–6.
   PubMed Web of Science ®Google Scholar
• Tagami M, Kimura F, Nakajima H, Ishida S, Fujiwara S, Doi Y, et al. Tracheostomy and invasive ventilation in Japanese ALS patients: decision-making and survival analysis: 1990–2010. J Neurol Sci. 2014;344:158–64.
   PubMed Web of Science ®Google Scholar
• Furuta N, Makioka K, Fujita Y, Okamoto K. Changes in the clinical features of amyotrophic lateral sclerosis in rural Japan. Intern Med. 2013;52:1691–6.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Atsuta N, Watanabe H, Hirakawa A, Watanabe H, Ito M, et al. Neck weakness is a potent prognostic factor in sporadic amyotophoic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2013;84:1365–77.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Dengener. 2015;16:230–6.
   PubMed Web of Science ®Google Scholar
• Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, Nakano I, et al. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2009;276:163–9.
   PubMed Web of Science ®Google Scholar
• Rabkin J, Ogino M, Goetz R, McElhiney M, Hupf J, Heitzman D, et al. Japanese and American ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): a cross-national survey. Amyotroph Lateral Scler Frontotemporal Dengener. 2014;15:185–91.
   PubMed Web of Science ®Google Scholar
• Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2012–2013. MMWR Surveill Summ. 2016;65:1–12.
   PubMed Web of Science ®Google Scholar
• Rechtman L, Jordan H, Wagner L, Horton DK, Kaye W. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph Lateral Scler Frontotemporal Dengener. 2015;16:65–71.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Simpson EP, Appel SH. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol. 2006;63:1139–43.
   PubMedGoogle Scholar
• Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997-2011. Neurol Clin Pract. 2013;3:313–20.
   PubMedGoogle Scholar
• Vender RL, Mauger D, Walsh S, Alam S, Simmons Z. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotroph Lateral Scler. 2007;8:36–41.
   PubMed Web of Science ®Google Scholar
• Kim WK, Liu X, Sandner J, Pasmantier M, Andrews J, Rowland LP, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009;73:1686–92.
   PubMed Web of Science ®Google Scholar
• Gundogdu B, Al-Lahham T, Kadlubar F, Spencer H, Rudnicki SA. Racial differences in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:114–18.
   PubMed Web of Science ®Google Scholar
• Paulukonis ST, Roberts EM, Valle JP, Collins NN, English PB, Kaye WE. Survival and cause of death among a cohort of confirmed amyotrophic lateral sclerosis cases. PLoS One. 2015;10:e0131965.
   PubMed Web of Science ®Google Scholar
• Miller RG, Anderson F, Brooks BR, Mitsumoto H, Bradley WG, Ringel SP, et al. Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database. Ann Neurol. 2009;65(suppl):S24–S8.
   Web of Science ®Google Scholar
• Sterling LE, Plowman EK, Simpson EP, Appel SH. Percutaneous endscopic gastrostomy (PEG) placement increases survival in amyotrophic laterel sclerosis: two decades in review. Amyotroph Lateral Scler Frontotemporal Dengener. 2014;15(suppl1):95–6.
   Google Scholar
• Al-Chalabi A, Calvo A, Chiò A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108–13.
   PubMed Web of Science ®Google Scholar
• Aridegbe T, Kandler R, Walters SJ, Walsh T, Shaw PJ, McDermott CJ. The natural history of motor neuron disease: assessing the impact of specialist care. Amyotroph Lateral Scler Frontotemporal Dengener. 2013;14:13–19.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatr. 2010;81:385–90.
   PubMed Web of Science ®Google Scholar
• Goldstein LH, Atkins L, Leigh PN. Correlates of quality of life in people with motor neuron disease (MND). ALS. And Other Motor Neuron Disorders. 2002;3:123–9.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G. Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. J Neurol Neurosurg Psych. 2010;81:1141–3.
   PubMed Web of Science ®Google Scholar
• Spataro R, Bono V, Marchese S, La Bella V. Tracheostomy mechanical ventilation in patients with amyotrophic lateral sclerosis: clinical features and survival analysis. J Neurol Sci. 2012;323:66–70.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psych. 2008;79:33–7.
   PubMed Web of Science ®Google Scholar
• Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:163–7.
   PubMed Web of Science ®Google Scholar
• O'Toole O, Traynor BJ, Brennan P, Sheehan C, Frost E, Corr B, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psych. 2008;79:30–2.
   PubMed Web of Science ®Google Scholar
• Dreyer P, Lorenzen CK, Schou L, Felding M. Survival in ALS with home mechanical ventilation non-invasively and invasively: a 15-year cohort study in west Denmark. Amyotroph Lateral Scler Frontotemporal Dengener. 2014;15:62–7.
   PubMed Web of Science ®Google Scholar
• Mitre B, Davidson M, Daxberg E-L, Jivegård L, Rosén H, Svanberg T, et al. Invasive ventilation in patients with amyotrophic lateral sclerosis and respiratory failure. Regional activity-based HTA. Gothenburg, Sweden. Regional Health Technology Assessment Centre Sahlgrenska University Hospital. 2014;72.
   Google Scholar
• LeBon B, Fisher S. Case report: Maintaining and withdrawing long-term invasive ventilation in a patient with MND/ALS in a home setting. Palliat Med. 2010;25:262–5.
   Web of Science ®Google Scholar
• O'Neil CL, Williams TL, Peel ET, McDermott CJ, Shaw PJ, Gibson GJ, et al. Non-invasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psych. 2012;83:371–6.
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, Veldink JH, Van der Tweel I, Kalmijn S, Beijer C, De Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003; 53:437–45.
   PubMed Web of Science ®Google Scholar
• Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS 40 mg/day: a double-blind, randomized, multicenter, placebo-controlled trial. Amyotroph Lateral Scler. 2009;10:378–83.
   PubMed Web of Science ®Google Scholar
• Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chiò A, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Dengener. 2013;14:397–405.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045–53.
   PubMed Web of Science ®Google Scholar
• Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;69:776–84.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–91.
   PubMed Web of Science ®Google Scholar
• Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy. Neurol Neuroimmunol Neuroinflamm. 2015;2:e100.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652–6.
   PubMed Web of Science ®Google Scholar